Skip to main content
ORASURE TECHNOLOGIES INC logo

ORASURE TECHNOLOGIES INC — Investor Relations & Filings

Ticker · OSUR ISIN · US68554V1089 LEI · 529900GNNJPNM4XHXQ77 US Manufacturing
Open in API
Filings indexed 1,018 across all filing types
Latest filing 2014-02-06 Director's Dealing
Country US United States of America
Listing US OSUR

About ORASURE TECHNOLOGIES INC

https://www.orasure.com/

OraSure Technologies, Inc. develops, manufactures, and distributes diagnostic products and sample collection tools. The company specializes in non-invasive technologies, particularly oral fluid-based solutions, to decentralize diagnostics and improve healthcare access. Its portfolio includes point-of-care and over-the-counter rapid tests for infectious diseases such as HIV and COVID-19. A notable achievement is the development of the first over-the-counter at-home HIV test. Through its subsidiaries, OraSure also provides sample management solutions for the collection of biological samples used in genomic, metabolomic, and microbiome research, serving healthcare providers, researchers, and consumers.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2014-02-06 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-06 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-06 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-06 English
PRIMARY DOCUMENT
Director's Dealing
2014-02-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 5, 2014, by OraSure Technologies, Inc. It includes multiple items: Item 2.02 reports the issuance of a press release announcing consolidated financial results for the quarter and full year ended December 31, 2013, and guidance for Q1 2014; Item 5.02 announces changes in senior management (retirement and promotion); Item 7.01 discloses a webcast conference call with prepared remarks attached. The document itself is a current report filing (8-K) that includes a press release and prepared remarks as exhibits. The press release is a financial results announcement (earnings release), and the prepared remarks correspond to a conference call transcript or summary. However, the 8-K document itself is a regulatory filing that includes these materials but is not the full earnings release or call transcript itself. Given the presence of management changes (Item 5.02) and financial results announcement (Item 2.02), the best classification is Regulatory Filings (RNS) because the document is a current report filing that includes multiple disclosures and attachments but is not solely an earnings release or call transcript. The document length (6495 characters) and content support this classification rather than a pure ER or CT filing. Therefore, the filing type code is RNS with high confidence.
2014-02-05 English

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.